Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|August 20, 2005
Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiationDan T Vogl, Eli Glatstein, Joseph R Carver, et al.
Clinical Nephrology|April 26, 2021
Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: A case series and systematic review of the literatureRachel Hilburg, Abdallah S Geara, Maylene Kefeng Qiu, et al.
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
JAMA Oncology|December 30, 2017
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysisAdam J Waxman, Suparna Clasen, Wei-Ting Hwang, et al.
European Journal of Haematology|December 5, 2022
Progressive multifocal leukoencephalopathy in multiple myelomaBrian W Hoeynck, Adam D Cohen, Edward A Stadtmauer, et al.
Blood|December 4, 2024
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myelomaDan T Vogl, Shebli Atrash, Sarah A Holstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaDan T Vogl, Noopur Raje, Sundar Jagannath, et al.
Nature Reviews. Nephrology|March 31, 2021
Kidney injury and disease in patients with haematological malignanciesFrank Bridoux, Paul Cockwell, Ilya Glezerman, et al.
Leukemia|February 15, 2019
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationNan Zhou, Alvaro Gutierrez-Uzquiza, Xiang Yu Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2025
A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple MyelomaTaxiarchis Kourelis, Sikander Ailawadhi, Dan T Vogl, et al.
Pageof 11